HRP20151438T1 - Sastavi stabilnih tiakumicina - Google Patents

Sastavi stabilnih tiakumicina Download PDF

Info

Publication number
HRP20151438T1
HRP20151438T1 HRP20151438TT HRP20151438T HRP20151438T1 HR P20151438 T1 HRP20151438 T1 HR P20151438T1 HR P20151438T T HRP20151438T T HR P20151438TT HR P20151438 T HRP20151438 T HR P20151438T HR P20151438 T1 HRP20151438 T1 HR P20151438T1
Authority
HR
Croatia
Prior art keywords
composition
pharmaceutical composition
diarrhea
enterocolitis
gallate
Prior art date
Application number
HRP20151438TT
Other languages
English (en)
Croatian (hr)
Inventor
Suketu Sanghvi
Mark Roach
Joseph F. Zhou
Ping He
Michael Mittleberg
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20151438T1 publication Critical patent/HRP20151438T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20151438TT 2007-01-19 2008-01-17 Sastavi stabilnih tiakumicina HRP20151438T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88113707P 2007-01-19 2007-01-19
EP08724557.7A EP2121716B1 (en) 2007-01-19 2008-01-17 Compositions of stable tiacumicins
PCT/US2008/000591 WO2008091518A1 (en) 2007-01-19 2008-01-17 Compositions of stable tiacumicins

Publications (1)

Publication Number Publication Date
HRP20151438T1 true HRP20151438T1 (hr) 2016-01-29

Family

ID=39641896

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151438TT HRP20151438T1 (hr) 2007-01-19 2008-01-17 Sastavi stabilnih tiakumicina

Country Status (22)

Country Link
US (2) US20080176927A1 (enExample)
EP (1) EP2121716B1 (enExample)
JP (2) JP5635266B2 (enExample)
KR (1) KR101491729B1 (enExample)
CN (2) CN102015747A (enExample)
BR (1) BRPI0806713A8 (enExample)
CA (1) CA2676003C (enExample)
CY (1) CY1117237T1 (enExample)
DK (1) DK2121716T3 (enExample)
ES (1) ES2560669T3 (enExample)
HR (1) HRP20151438T1 (enExample)
HU (1) HUE028671T2 (enExample)
IL (1) IL199941A (enExample)
MX (1) MX2009007784A (enExample)
NZ (1) NZ578493A (enExample)
PL (1) PL2121716T3 (enExample)
PT (1) PT2121716E (enExample)
RU (1) RU2484829C2 (enExample)
SI (1) SI2121716T1 (enExample)
TW (1) TWI474820B (enExample)
WO (1) WO2008091518A1 (enExample)
ZA (1) ZA200905134B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
BR112012029259A8 (pt) * 2010-05-18 2021-03-23 Optimer Pharmaceuticals Inc tratamento de infecção por clostridium difficile em pacientes sob terapia de antibióticos
WO2011146624A2 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Methods of treating recurring bacterial infection
EP2575487B1 (en) * 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
MX2013009033A (es) * 2011-02-04 2013-09-06 Optimer Pharmaceuticals Inc Tratamiento de infecciones bacterianas.
ITMI20120560A1 (it) 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
PT3139932T (pt) * 2014-05-09 2018-11-14 Astellas Pharma Europe Ltd Regime de tratamento para composto de tiacumicina
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN112353774B (zh) * 2020-11-17 2022-08-23 浙江汇能生物股份有限公司 一种那西肽风味咀嚼片及其制备方法及其在犬魏氏梭菌病上的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05192094A (ja) * 1991-09-03 1993-08-03 Takeda Chem Ind Ltd 造粒組成物
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
AU2003251902B2 (en) * 2002-07-29 2008-03-06 Merck Sharp & Dohme Llc Tiacumicin production
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
EP1572164A2 (en) * 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
MX2007009196A (es) 2005-01-31 2009-02-25 Optimer Pharmaceuticals Inc Compuestos macrocilicos de 18 miembros y analogos de los mismos.

Also Published As

Publication number Publication date
KR101491729B1 (ko) 2015-02-09
NZ578493A (en) 2012-02-24
US20080176927A1 (en) 2008-07-24
ES2560669T3 (es) 2016-02-22
JP5635266B2 (ja) 2014-12-03
CN102015747A (zh) 2011-04-13
MX2009007784A (es) 2010-02-11
IL199941A (en) 2016-02-29
EP2121716A1 (en) 2009-11-25
CA2676003C (en) 2012-04-10
ZA200905134B (en) 2013-08-28
EP2121716A4 (en) 2013-06-12
US20130065844A1 (en) 2013-03-14
AU2008209623A2 (en) 2010-01-28
JP2010516677A (ja) 2010-05-20
BRPI0806713A8 (pt) 2017-04-18
EP2121716B1 (en) 2015-12-09
BRPI0806713A2 (pt) 2011-09-13
CN105169396A (zh) 2015-12-23
AU2008209623A1 (en) 2008-07-31
IL199941A0 (en) 2010-04-15
TW200938187A (en) 2009-09-16
JP2014205701A (ja) 2014-10-30
TWI474820B (zh) 2015-03-01
RU2009128612A (ru) 2011-02-27
SI2121716T1 (sl) 2016-03-31
RU2484829C2 (ru) 2013-06-20
PT2121716E (pt) 2016-03-03
HUE028671T2 (en) 2016-12-28
WO2008091518A1 (en) 2008-07-31
KR20090107061A (ko) 2009-10-12
DK2121716T3 (en) 2016-03-14
CY1117237T1 (el) 2017-04-05
PL2121716T3 (pl) 2016-04-29
CA2676003A1 (en) 2008-07-31
JP5995331B2 (ja) 2016-09-21

Similar Documents

Publication Publication Date Title
HRP20151438T1 (hr) Sastavi stabilnih tiakumicina
JP2010516677A5 (enExample)
KR20140075754A (ko) 7-[4-(4-벤조[ｂ]티오펜-4-일-피페라진-1-일)부톡시]-1Ｈ-퀴놀린-2-온 또는 그 염을 함유하는 정제
MX2011005633A (es) Formas de dosificacion solida de bendamustina.
HRP20151095T1 (hr) Farmaceutski pripravci koji sadrže rifaksimin, postupci za njihovu proizvodnju i njihova primjena u lijeäśenju vaginalnih infekcija
HRP20161231T1 (hr) Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore
HRP20221381T1 (hr) C-manozidni spojevi korisni za liječenje infekcija urinarnog trakta
CA2735926C (en) Pharmaceutical composition for use in treating sexually transmitted infections
AR080895A1 (es) Formulacion de comprimido de ezatiostat
HRP20161635T1 (hr) Novi derivati monenzina za liječenje i prevenciju protozoalnih infekcija
US20230248745A1 (en) Silver enhanced cannabinoid antibiotics
EP2678015B1 (en) Use of nifuratel to treat infections caused by clostridium species
RU2009101126A (ru) Фармацевтическая композиция с антипсихотическим действием
HRP20221338T1 (hr) Primjena totarola i farmaceutski pripravak koji sadrži totarol
RU2014124118A (ru) Фармацевтические препараты, включающие аторвастатин и глимепирид
ES2280150T1 (es) Combinacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, composicion de la misma y preparacion y uso de la misma.
AU2008209623B2 (en) Compositions of stable tiacumicins
DK2648704T3 (en) Antimicrobial composition
HK1187553B (en) Use of nifuratel to treat infections caused by clostridium species
HK1156322A (en) Compositions of stable tiacumicins
CN103505459A (zh) 利奈唑胺药物组合物
AU2013254941A1 (en) Compositions of stable tiacumicins